Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 99.95 -1.40 (-1.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday February 27, 2024 U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session February 27, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 27, 2024 Via Benzinga Ligand Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Ligand Pharmaceuticals's Earnings: A Preview February 26, 2024 Via Benzinga Where Ligand Pharmaceuticals Stands With Analysts September 19, 2023 Via Benzinga Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® February 22, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires February 16, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 13, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Analyst Expectations for Ligand Pharmaceuticals's Future August 23, 2023 Via Benzinga U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum January 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance December 12, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City December 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications December 01, 2023 From Palvella Therapeutics Via GlobeNewswire Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's November 28, 2023 Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent Via Benzinga Ligand Reports Third Quarter 2023 Financial Results November 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million November 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand To Report Third Quarter 2023 Financial Results On November 8 October 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 October 18, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ligand Acquires Assets of Novan, Inc. for $12.2 Million September 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Appoints Martine Zimmermann to its Board of Directors September 26, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma September 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control September 21, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary September 19, 2023 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... Via Benzinga Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio September 18, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Second Quarter 2023 Financial Results August 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials July 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.